Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
- PMID: 17327617
- DOI: 10.1200/JCO.2006.09.8137
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Comment on
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.J Clin Oncol. 2006 Oct 20;24(30):4922-7. doi: 10.1200/JCO.2006.07.1316. J Clin Oncol. 2006. PMID: 17050876 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials

